BRAIN Biotech AG
XETRA:BNN
Intrinsic Value
BRAIN Biotech AG is a technology company, which engages in the development and commercialization of bioactives, natural compounds, and proprietary enzymes. [ Read More ]
The intrinsic value of one BNN stock under the Base Case scenario is 6.97 EUR. Compared to the current market price of 2.83 EUR, BRAIN Biotech AG is Undervalued by 59%.
Valuation Backtest
BRAIN Biotech AG
Run backtest to discover the historical profit from buying and selling BNN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
BRAIN Biotech AG
Current Assets | 22.1m |
Other Current Assets | 22.1m |
Non-Current Assets | 44.4m |
Other Non-Current Assets | 44.4m |
Current Liabilities | 13.4m |
Other Current Liabilities | 13.4m |
Non-Current Liabilities | 32.6m |
Other Non-Current Liabilities | 32.6m |
Earnings Waterfall
BRAIN Biotech AG
Revenue
|
55.2m
EUR
|
Cost of Revenue
|
-24.2m
EUR
|
Gross Profit
|
31m
EUR
|
Operating Expenses
|
-36.7m
EUR
|
Operating Income
|
-5.7m
EUR
|
Other Expenses
|
-2.7m
EUR
|
Net Income
|
-8.4m
EUR
|
Free Cash Flow Analysis
BRAIN Biotech AG
BNN Profitability Score
Profitability Due Diligence
BRAIN Biotech AG's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
BRAIN Biotech AG's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
BNN Solvency Score
Solvency Due Diligence
BRAIN Biotech AG's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Score
BRAIN Biotech AG's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BNN Price Targets Summary
BRAIN Biotech AG
According to Wall Street analysts, the average 1-year price target for BNN is 10.27 EUR with a low forecast of 4.14 EUR and a high forecast of 15.75 EUR.
Shareholder Return
BNN Price
BRAIN Biotech AG
Average Annual Return | -11.56% |
Standard Deviation of Annual Returns | 20.92% |
Max Drawdown | -79% |
Market Capitalization | 61.8m EUR |
Shares Outstanding | 21 847 495 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
BRAIN Biotech AG is a technology company, which engages in the development and commercialization of bioactives, natural compounds, and proprietary enzymes. The company is headquartered in Zwingenberg, Hessen and currently employs 293 full-time employees. The company went IPO on 2016-02-09. Research & Development activities focus on bioactive natural compounds, tailored enzymes and high-performance microorganisms.
Contact
IPO
Employees
Officers
The intrinsic value of one BNN stock under the Base Case scenario is 6.97 EUR.
Compared to the current market price of 2.83 EUR, BRAIN Biotech AG is Undervalued by 59%.